BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic.

。

Also Read: FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax’s Shot.

另请阅读：FDA批准了辉瑞（Pfizer）和摩德纳（Moderna）最新的新型冠状病毒疫苗，但遗漏了诺瓦克斯（Novax）的疫苗。

These companies, whose stocks plummeted by about 80% since their 2021 pandemic peaks, are now focusing on cancer treatments to revive their fortunes.

这些公司的股票自2021年大流行高峰以来暴跌了约80%，现在正专注于癌症治疗以恢复其财富。

The personalized approach, though promising, faces skepticism due to the high cost and difficulty of scaling production.

个性化方法虽然很有前景，但由于成本高且难以规模化生产而受到质疑。

Miranda Payne, a melanoma specialist leading a Moderna trial at Oxford’s Churchill Hospital, expressed excitement about the potential but noted the challenges in making these vaccines widely available.

米兰达·佩恩（MirandaPayne）是牛津丘吉尔医院（Oxford'sChurchill Hospital）一名黑色素瘤专家，领导了一项Moderna试验，他对这种疫苗的潜力表示兴奋，但指出了在广泛使用这些疫苗方面面临的挑战。

The Financial Times notes the high cost of sequencing each patient’s tumor and producing bespoke vaccines raises concerns about the feasibility of widespread application.

英国《金融时报》指出，对每位患者的肿瘤进行测序和生产定制疫苗的成本很高，这引发了人们对广泛应用可行性的担忧。

Moderna’s melanoma vaccine, developed in partnership with Merck & Co Inc MRK, is in advanced trials, while BioNTech’s product, co-developed with Roche Holdings AG’s RHHBY subsidiary Genentech, is being tested in an NHS trial.

与默克公司（Merck＆Co Inc）MRK合作开发的Moderna黑色素瘤疫苗正在进行高级试验，而与罗氏控股公司（Roche Holdings AG）的RHHBY子公司Genentech共同开发的BioNTech产品正在NHS试验中进行测试。

Also Read: Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients.

另请阅读：摩德纳，默克公司公布了高危黑色素瘤患者个体化癌症治疗的三年数据。

Despite the optimism, experts caution that while the individual approach is exciting, the high costs and challenges of production make it uncertain whether these personalized vaccines will be scalable or affordable.

尽管乐观，但专家警告说，虽然个别方法令人兴奋，但生产的高成本和挑战使得这些个性化疫苗是否具有可扩展性或价格合理尚不确定。

Uğur Şahin, CEO of BioNTech, emphasized the importance of innovation in personalizing mRNA vaccines, predicting that these treatments could be as impactful as existing immunotherapies by 2030.

BioNTech首席执行官UğurŞahin强调了个性化mRNA疫苗创新的重要性，预测到2030年，这些治疗方法可能与现有免疫疗法一样具有影响力。

Moderna is likely to bring its cancer vaccine to market first, focusing on lung and skin cancers. The company is also investing in new manufacturing facilities to improve production efficiency. BioNTech is taking a dual approach, developing personalized and off-the-shelf vaccines to address different cancer types..

Moderna可能会首先将其癌症疫苗推向市场，重点关注肺癌和皮肤癌。该公司还投资建造新的制造设施，以提高生产效率。。。

As BioNTech and Moderna push forward, the cancer treatment landscape could be transformed, but the journey is fraught with obstacles.

随着生物技术公司（BioNTech）和摩德纳（Moderna）的推进，癌症治疗领域可能会发生改变，但这段旅程充满了障碍。

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

免责声明：此内容部分是在AI工具的帮助下制作的，并由Benzinga编辑审阅和发布。

Read Next:

阅读下一页：

NewAmsterdam Pharma’s Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside.

新阿姆斯特丹制药公司（NewamsterdamPharma）的胆固醇类药物销售火爆，看涨的分析师认为其前景广阔。

Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga API为您带来的市场新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。